In Vivo Bioavailability and Therapeutic Assessment of Host-Guest Inclusion Phenomena for the Hydrophobic Molecule Etodolac: Pharmacodynamic and Pharmacokinetic Evaluation by Sinha, Vivek Ranjan et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
In Vivo Bioavailability and Therapeutic 
Assessment of Host-Guest Inclusion Phenomena 
for the Hydrophobic Molecule Etodolac: 
Pharmacodynamic and  
Pharmacokinetic Evaluation 
Vivek Ranjan SINHA *, AMITA, Honey GOEL 
University Institute of Pharmaceutical Sciences, Panjab University,160014,Chandigarh, India  
* Corresponding author. E-mail: sinha_vr@rediffmail.com (V. R. Sinha) 
Sci Pharm. 2010; 78: 103–115        doi:10.3797/scipharm.0909-08 
Published:   January 18
th  2010    Received:    September  17
th 2009 
Accepted:   January 18
th 2010 
This article is available from: http://dx.doi.org/10.3797/scipharm.0909-08 
© Sinha et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
The aim of present investigation was 1) to evaluate the in vivo bioavailability of 
an Etodolac (ETD)-β-cyclodextrin (β-CD) inclusion complex system prepared by 
kneading and spray drying techniques in rats, 2) to study the pharmacodynamic 
parameters in various animal models for analyzing the therapeutic response 
and, 3) to evaluate the pharmacokinetic profile of the drug administered. 
Inclusion complexation with β-CD enhanced the solubility of the drug, improved 
bioavailability and reduced ulcerogenicity of ETD in rats. Pharmacodynamic 
studies were carried out in normal LACA mice and pharmacokinetic evaluation 
was done in male Wistar rats. Pharmacokinetic parameters evaluated for the 
inclusion complexes revealed good correlation. The minimum dose necessary 
to produce analgesic or anti-arthritic activity was also decreased, indicating that 
the host-guest strategy that uses β-CD and ETD was very effective and could 
be successfully employed in the preparation of pharmaceutical formulations of 
anti-arthritics and analgesics. 
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Introduction  
ETD [(±)-1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic  acid] is an indole 
analog which acts as an analgesic (selective COX-2 inhibitor) and anti-inflammatory drug 
especially for the treatment of arthritis. The anti-inflammatory activity of ETD has been 
reported to be mainly due to the inhibition of prostaglandin biosynthesis [1]. This drug has 
a very poor solubility in water and this limits its use to solid dosage forms for oral 
administration. The major drawbacks associated with the NSAIDs are local gastrointestinal 
toxicity and ulceration. Upon chronic use, gastrolestivity lead to termination of NSAID 
therapy in such conditions. ETD, being a practically insoluble candidate, was evaluated for 
its toxicity and therapeutic assessment in the rats locally, as systemic side-effects were 
less prominent.  
Recently, clinical studies have revealed that ETD chemically induced anticarcinogenic 
effects on various human carcinoma cell lines [2, 3] and have shown chemopreventive 
action on biliary carcinogenesis in hamsters [4]. Hence, ETD has revitalized the interest 
among the researchers for better management of NSAID therapies to widen the scope of 
therapeutic options for antiarthritis. Inclusion-complexation via cyclodextrins is one of the 
strategic tool for clinically useful candidates like ETD with poor preformulation 
characteristics. However, various investigations pertaining to complexation using ETD has 
been reported like solid dispersions [5–7].  
In our previous work, we successfully encapsulated the hydrophobic molecule ETD into 
the CD moiety and enhanced various physiochemical factors like solubility behavior and 
dissolution rate [8]. Hence, the aim of the present study was to evaluate the in-vivo 
bioavailability and therapeutic assessment of ETD-β-CD complexes in male LACA mice or 
wistar rats. The pharmacodynamics of the inclusion complexes to study effect of toxicity on 
local tissues and pharmacokinetic profile to assess the bioavailability and peak plasma 
concentration was elucidated. 
Results and Discussion 
Pharmacodynamic studies 
The data of in vivo pharmacological responses (% analgesic effect) versus time for mice 
has been displayed in Fig.1. Initially the response was low due to slow absorption of the 
drug. A significant difference in the response of the 1:1 inclusion complexes (KD1) was 
observed at a time point of 1 h, 2 h and 4 h. It was highest after two hours of 
administration however after that there was a decline in the response. This may be 
attributed to decrease in the therapeutic level in the blood. However, KD2 exhibited a 
significant difference at 2 h and 4 h. The peak response was observed at 2 h in case of 
both the complexes as well as the pure drug. The response exhibited by the inclusion 
complexes, KD1 and KD2 was 1.33 and 1.27 fold higher respectively as compared to the 
pure drug at 2 h. Analgesic response exhibited by SD was significantly higher at all time 
points in comparison to pure drug, physical mixture and both the kneaded complexes i.e. 
KD1 and KD2. This data suggests that inclusion complexation was helpful in enhancing 
the analgesic response of the ETD. 
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Fig. 1.   Percentage analgesic response of KD1, KD2, and SD as compared to the pure 
drug ETD (n=5, dose~10mg/kg of drug). 
Acetic acid induced writhing for the determination of analgesic response of 
complexes over pure drug 
The percentage analgesic response for the inclusion complexes was significantly higher 
for the inclusion complexes when compared with the pure drug as well as the physical 
mixture (Fig. 2). This suggests that the inclusion complexes were more effective in 
preventing the acetic acid induced writhings. This can be attributed to the better absorption 
of the drug from the inclusion complexes as compared to the pure drug and the physical 
mixtures. The percentage analgesic response was 1.70 times higher in case of KD1 when 
compared with that of the pure drug. In case of KD2, it was 1.53 times higher in 
comparison of the pure drug. SD showed 1.56 times higher analgesic effect in comparison 
to pure drug. When compared with that of the physical mixture, KD1 and KD2 showed a 
1.24 and 1.12 times which was significantly (p<0.05) higher analgesic response 
respectively. For SD, percent analgesic effect was 1.15 times higher than the physical 
mixture. These data suggests that inclusion complexation was helpful in enhancing the 
analgesic response of the ETD. 
 106  V. R. Sinha, Amita and H. Goel:   
Sci Pharm. 2010; 78; 103–115. 
Fig. 2.   Percentage analgesic response of KD1, KD2, SD as compared to the pure ETD 
(n=5, dose~10mg/kg of drug)  
Anti-inflammatory activity 
The % anti-inflammatory activity for the inclusion complexes, KD1 and KD2 was 
significantly higher than that of pure drug, suggesting that the inclusion complexes were 
more effective in preventing the rat paw edema caused by the carrageenan (Fig. 3).  
 
Fig. 3.   Percentage inhibition of inflammation of KD1, KD2, SD, ETD and the PM1(n=5, 
dose~10mg/kg of drug). 
This can be attributed to the higher drug release from the inclusion complexes as 
compared to the pure drug and the physical mixtures. Significant difference (p<0.05) was 
observed at all the time intervals in case of KD1 complex except at 1 h and 4 h time 
interval, in comparison to the pure drug. KD2 complex also showed a significant difference 
from pure drug at 2 h, 3 h and 4 h time interval. The physical mixture showed a higher anti-
inflammatory response which was significant only at 3 h in comparison to the pure drug. 
The lowest anti-inflammatory response was obtained by the pure drug. Highest response 
was observed at 3 h in case of both the kneaded complexes. The response with KD1 or 
KD2 was 2.35 times and 2.45 times higher than that of the pure drug at 3 h respectively. 
Physical mixture showed a response that was 1.85 times that of the pure drug at 3 h. 
These observations showed that inclusion complexes were more effective in inhibiting the 
anti-inflammatory response of carrageenan. SD complex also showed a significantly 
higher (p<0.05) anti-inflammatory response at 2 h and 3 h in comparison to both pure drug 
and physical mixture. In comparison to the physical mixture all the complexes showed 
higher anti-inflammatory response at different time points. KD1 showed a significant 
difference (p<0.05) at 1 h, 2 h and 6 h while KD2 showed a significant difference at 2 h, 
3 h and 6 h in comparison to the physical mixture.  
Antiulcer activity 
Presence of the undissolved particles of the drug in contact with the gastric mucosa leads 
to high local concentration of the drug. This high concentration leads to local irritation and 
finally causes ulceration of the mucosa. The complexation of the drug with β-CD, promotes 
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undissolved particles adhering to the gastric mucosa leading to the reduction in the 
ulcerative tendency of the drug. Minor ulceration produced in the inclusion complexes of 
the drug can be due to the systemic effect of the drug, resulting from the inhibition of the 
synthesis of prostaglandins PGI1 and PGE2, which have a protective action on the gastric 
mucosa. Based upon the ulcer index, the antiulcer activities for the various groups were 
classified on scale [9]. For the acute gastric damage, ETD produced significant 
augmentation in ulcer activity (with the ulcer index of 5.0) index as compared to control 
group and the complex treated one (Table 1). All the complexes showed better antiulcer 
activity, However, kneaded complexes KD1, KD2 exhibited better antiulcer activity as 
compared to spray dried complex (SD). On uclerogenic scale, SD showed a higher ulcer 
index (SD =1.5; KD1=1; KD2 =1). This may be attributed to the presence of some 
uncomplexed drug as supported by DSC studies [8]. 
Tab.1.   Anti-ulcer activity of various formulations in rats (n=5, dose eqv. ~10 mg/kg of 
drug) 
Group Ulcer  Index
a 
CMC (Control)  0.5 ± 1.02 
ETD  5.0 ± 2.11 
PM1  2.0 ± 2.17 
KD1  1.0 ± 1.23 
KD2  1.0 ± 1.44 
SD  1.5 ± 1.09 
a Data represent mean ± S.D. 
 
Tab. 2.   Statistical comparison of various pharmacokinetic parameters of ETD, SD, 
KD1(mean± S.D)
a 
Subject Tmax (h) Cmax  
(ng/ml) 
AUCt 
(ng×h/ml) 
AUC∞ 
(ng×h/ml) 
Ka 
(h
−1) 
Kel  
(h
−1) 
T½ 
(h) 
Etodolac 3.0  ± 
0.0 
2.795 ± 
0.35 
17.383 ± 
1.22 
17.936 ± 
1.20 
0.309 ± 
0.028 
0.148 ± 
0.011 
4.41 ± 
0.85 
SD 3.0  ± 
0.0 
7.014 ± 
2.97* 
31.099 ± 
6.93* 
44.971 ± 
4.54* 
0.379 ± 
0.020* 
0.035 ± 
0.009* 
20.768 ± 
4.87* 
KD1 3.0  ± 
0.0 
4.866 ± 
0.07* 
43.846 ± 
6.5* # 
45.537 ± 
4.94* 
0.441 ± 
0.167 
0.152 ± 
0.04*# 
8.34 ± 
6.90*# 
a Data represent mean ± S.D. (standard deviation); * Significantly different from group I at 95% 
level determined by applying one-way ANOVA followed by Tukey’s studentized t-test; 
# 
Significantly different from group SD at 95% level determined by applying one way ANOVA 
followed by Tukey’s studentized t-test. 
 
Pharmacokinetic studies 
Pharmacokinetic evaluation of ETD (Fig. 4a) as well as the inclusion complexes was 
carried out in wistar male rats for 24 hours. Various pharmacokinetic parameters were 
calculated using PC-NONLIN software and were statistically compared using one way 
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different (p<0.05) for other formulations in-vivo. For the pharmacokinetic profile of ETD, 
average max. concentration in plasma was found to be 2.79 ng/ml within 3 hrs after the 
oral administration of the drug. However, there was a decrease in the concentration 
suggesting fast elimination of ETD. The average elimination rate constants and AUC after 
the administration of pure drug was obtained to be 0.149 h
−1 and 17.38 ngh/ml 
respectively.  
In vivo plasma studies using kneaded inclusion complexes 
Pharmacokinetics of the complexes was performed in order to study its effect on the 
bioavailability of the drug and the data obtained was compared with that of pure drug. After 
administration of a single dose of 10 mg/kg, the plasma levels (AUC0–24h) were analyzed 
for the pure ETD over the next 24 h period. The mean serum concentration vs time profile 
for pure drug and KD1 has been depicted (Fig. 4b). Following the oral administration, the 
plasma levels increased sharply whereas Cmax value reached within 3 h post dose. The 
average Cmax value for the complex was 4.86 ng/ml, which was 1.74 times higher as 
compared to that observed with the pure drug. The tmax of the complex was almost similar 
to that of the pure drug but the extent of absorption was much higher in case of the 
complex as compared to the pure drug. It can be concluded from the values of AUCt~ 
43.84 ngh/ml that complexes exhibited greater absorption as compared with the pure drug 
(AUCt ~17.38 ngh/ml). This data revealed that the complex had 2.52 times higher 
bioavailability as compared to the pure drug. The t1/2 (8.34 h) was prolonged (1.89 fold 
more) in case of the complex as compared with pure drug (4.41 h). Also, the Ke was 
0.152 h
−1 which was 0.148 h
−1 in case of the pure drug showing that the absorption time of 
the drug has been increased. Based upon these observations, it can be inferred that the 
bioavailability of the drug was increased with the inclusion complexation. 
Using spray dried complex 
Spray dried complexes were orally administered (single oral dose of 10 mg/kg) in rats in 
order to study its effect on the bioavailability of the drug in comparison to pure drug. The 
plasma levels were analyzed for the pure ETD over the next 24 h period. Fig. 4c shows the 
mean serum concentration vs time profile for the spray dried complex indicating sharp 
increase in plasma levels after oral administration. Cmax for the complex reached at 3 h 
post dose was found to be 7.01 ng/ml (2.51 times higher) as compared to pure drug. The 
tmax of the complex was almost similar to that of the pure drug but the extent of absorption 
was much higher.  
Furthermore, AUCt of the complex was found to be ~31.099 ngh/ml as compared to the 
pure drug AUCt~17.38 ngh/ml which revealed greater absorption (1.79 times more) of 
spray dried complex than pure drug. The t1/2 (20.76 h) was prolonged (4.71 times) in case 
of the complex when compared with that of the pure drug (4.41 h). Also, the ke was 
decreased (0.04  h
-1) which was 0.15  h
-1 in case of the pure drug showing that the 
absorption time of the drug has been increased.  
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Fig. 4.   Mean plasma concentration (AUC0–24h) time profile of pure drug and complexes 
in wistar rats (n=5, dose eqv.~ 10mg/kg of drug) a) ETD, b) KD1, c) SD  110  V. R. Sinha, Amita and H. Goel:   
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The curve fitting using least square technique models were used to evaluate the 
correlation between the mean plasma concentration (AUC0–24h) vs time profile of 
complexes against time in comparison with pure drug as shown in the Fig. 5.  
(a) (b) 
 
(c) 
 
Fig. 5.  Correlation of mean plasma concentration (AUC0–24h) vs time at different 
intervals for pure drug as well as inclusion complexes (a) ETD (b) KD1 and (c) 
SD 
The mean plasma concentration (AUC0–24h)-time profile was subjected to curve fitting 
models using least square method to evaluate the correlation between pure drug or 
complexes at different time. The r
2 value of 0.05 for ETD, 0.316 for KD1 (p<0.05) and 
0.168 for SD (p<0.05) were obtained form the profile data. 
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Experimental 
Materials 
ETD was obtained as gift sample from Ranbaxy Pvt. Ltd., (Gurgaon, India) and β-CD was 
obtained from S.A Chemicals (Mumbai, India). Freshly prepared tripled distilled water was 
used throughout the study. All the chemicals and solvents used were of analytical grade. 
Preparation of binary inclusion complexes  
Kneading and Spray drying techniques were used for the preparation of inclusion 
complexes. The physiochemical characterization and in-vitro dissolution of the inclusion 
complexes have been well testified in our earlier study [8]. Physical mixtures of ETD and in 
a molar ratio of 1:1 (PM1) with β–CD was prepared by passing the drug and β–CD through 
mesh #60 separately and then mixing both solids by simple blending.  
Pharmacodynamic Studies  
All the pharmacodynamic studies were carried out on normal LACA mice in accordance 
with the guidelines of Institutional Animal Care and Use Committee (IACUC). All animals 
were acclimatized to the laboratory environment before use and were fed on standard 
normal pellet diet (Aashirwad Industries, Chandigarh) and water ad libitum.  
Measurement of Analgesic Activity  
Tail Flick Method 
Tail flick technique was followed to observe the analgesic parameters with the help of 
Analgesiometer (Popular India Ltd.). Animals (mice) were weighed and basal reaction time 
of radiant heat was recorded by placing the tip of the tail on radiant heat source. The tail 
withdrawal from the heat (flicking response) was taken as the end point. A cut off period of 
12 seconds was observed to prevent damage to the tail. Six male LACA mice (each of 
weight 18–25g) were divided into four groups. Group I, group II, group III and group IV 
received pure drug, KD1, KD2 and SD respectively. Each group received the respective 
formulation (in a dose equivalent to 10 mg/kg of drug) orally. Percent analgesic effect was 
measured as follows: 
Eq. 1.  
value   Baseline     value   Cutoff
value   Baseline     Response   Observed
    Effect    Analgesic %
−
−
=  
Acetic Acid Induced Writhing 
Another animal model followed for evaluation of analgesic activity was abdominal writhing 
assay. Six normal LACA mice (weighing 18–25 g) were divided into five groups each. 
Group I, group II, group III, group IV and group V received pure drug, PM1, KD1, KD2 and 
SD respectively. Each group received the respective formulation (in a dose equivalent to 
10 mg/kg of drug) orally. Writhing response was elicited by intraperitoneal (i.p.) injection of 
freshly prepared acetic acid solution (0.6%, 10 ml/kg, i.p.). The number of writhes 
(constriction of abdomen, turning of trunk, and extension of hind limbs) due to acetic acid 
was expressed as a nociceptive response. The number of writhes per animal was counted 
during a 30 min. period, beginning 3 min. after the injection of acetic acid. Percent 
analgesic effect was measured as follows: 112  V. R. Sinha, Amita and H. Goel:   
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Eq. 2.  
complex   for   Response
complex   for   Response     control   for   Response
    Effect    Analgesic %
−
=  
Evaluation of Anti-Inflammatory Response 
Carrageenan Induced Rat Paw Edema   
Ugo Basile plethysmometer was used to measure the paw volume as an indication of the 
inflammation. Animals were weighed, numbered and marked on both the hind paws just 
beyond tibio-tarsal junction, so that every time the paw was dipped in the surfactant 
column up to the fixed mark to ensure constant paw volume. Initial paw volume (both right 
and left) of each rat was noted by volume displacement method.  
Six animals were divided into six groups: control, pure drug treated, KD1, KD2, SD and 
PM. Group I, II, III, IV and V received pure drug, PM1, KD1, KD2 and SD respectively. 
Further, each group received the respective formulation (in a dose equivalent to 10 mg/kg 
of drug) orally. All the calculations were done with respect to control group. After 30 
minutes, 0.1 ml of 1% w/v carrageenan was injected in the plantar region of the left paw of 
the control group as well as all the groups. The right paw served as a reference non-
inflamed paw for comparison. Paw volume of both the legs of three groups and control 
were measured at 1 h, 2 h, 3 h, 4 h and 6 h after carrageenan challenge. Percent edema 
inhibition by the test substance was determined as follows: 
Eq. 3.   100
Control
Test     Control
    on inflammati   of   Inhibition   % ⋅
−
=  
Antiulcer activity 
The antiulcer activity of the complexes formed was evaluated by testing the complexes for 
their therapeutic uclerogenic index in mice. Six animals divided into six groups were kept 
on fasted state for 18 h. Group I was kept as control while groups (II, III, IV, V, and VI) 
received pure drug, PM1, KD1, KD2 and SD respectively. Control group received 0.5% 
carboxymethyl cellulose (CMC) while, other groups received the respective formulation (in 
a dose equivalent to 10 mg/kg of drug) orally. Animals were sacrificed 7 h after the 
treatment. The stomach was removed, opened along the greater curvature, washed with 
saline, and observed for ulcers. The ulcers were scored on the following uclerogenic index 
scale [9]. 
HPLC method for estimation of ETD in plasma  
100 mg of drug was dissolved in 100 ml of hydro-alcoholic solution. 10 ml of this solution 
(1 mg/ml) was diluted to 100 ml with triple distilled water to make stock solution of 
100 µg/ml. The standards for calibration curve were prepared by adding known amount of 
ETD to plasma in the range of 100 ng-40 µg/ml. The method for the drug estimation in 
plasma was validated by RP-HPLC system (LC-10 AT VP Shimadzu pump equipped with 
a SPD-10 AV P Shimadzu UV- visible detector) consisted of a mobile phase with 
composition of Acetonitrile: buffer (pH 4.75) (in the ratio of 45:55), at a flow rate of 1.0 
mL/min, a C-18 reverse phase column (YMC HPLC column, YMC Co. Ltd. Japan, 250 x 
4.6 mm, S-5µ), an injection volume of 20 µL and ultraviolet (UV) detection at wavelength of 
225nm.   Pharmacodynamic and Pharmacokinetic Evaluation of Inclusion Complexes of Etodolac  113 
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Pharmacokinetic Studies 
Pharmacokinetic studies were performed on Wistar male rats (by administering pure drug 
as well as the complexes orally) in order to determine the plasma level profiles of pure 
ETD and inclusion complexes. The pharmacokinetic profiles of pure drug and inclusion 
complexes administered orally were statistically compared to evaluate the therapeutic 
efficacy and in-vivo bioavailability of the complexes. Animals were handled and housed in 
accordance with the guidelines of IACUC. Five Wistar male rats were divided into three 
groups consisting of pure drug treated (group I), KD1 (group II) and SD (group III). Each 
group received the respective formulation (in a dose equivalent to 10 mg/kg of drug) orally. 
After oral dose, blood samples were withdrawn at 0, 0.5, 1, 2, 3, 6, 12 and 24 h intervals. 
Blood samples were collected in Ependroff tubes containing heparin. Immediately upon 
collection, blood samples were centrifuged (5000 rpm for 5 min) and separated plasma 
was kept at –20°C if not analyzed immediately. They were subjected further for HPLC 
analysis.  
Statistical Analysis and Curve Fitting 
Plasma concentration time profiles were evaluated by fitting these to suitable 
compartmental approach. Various pharmacokinetic parameters (t1/2, Cmax, Tmax , AUC, t1/2a, 
Kel and Ka) were evaluated using PC-NONLIN software. The pharmacokinetic parameters 
obtained were evaluated for the significance at 95% level determined by applying one-way 
ANOVA followed by Tukey’s studentized t-test.  
SPSS
® (version 16.0) curve-fitting program using least square technique was used to 
evaluate the correlation between the mean plasma concentration(AUC0–24h) against 
different time intervals and compare their relative goodness of fit for models where a single 
dependent variable is predicted by a single independent variable or by a time variable as 
shown in Fig. 5.  
Conclusion 
A significant difference in the percentage analgesic response of the inclusion complexes 
as compared to that of the pure drug was found. The in vivo pharmacokinetic studies after 
the oral administration of the inclusion complexes showed an enhanced extent of 
absorption in comparison to the pure drug and the physical mixtures. An increase in the t1/2 
and decrease in the elimination rate supported the fact that the drug was available for the 
absorption for a longer time. From these observations, it can be concluded that inclusion 
complexion phenomena led to enhanced bioavailability (KD1 caused 2.52 times whereas 
SD increased 1.79 times) than that of pure drug. The order of augmentation of 
bioavailability was KD1 > SD >PM1 the bioavailability of the drug was increased with the 
spray dried inclusion complexation. The host–guest strategy that uses β-CD and ETD was 
found to be very effective and could be successfully employed in the preparation of 
pharmaceutical formulation of anti-arthritics and analgesics. 
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